The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO
S Di Cosimo, C Campbell, H A Azim, G Galli, G Bregni, G Curigliano, C Criscitiello, M Izquierdo, L De La Pena, D Fumagalli, L Fein, J Vinholes, W M J Ng, M Colleoni, A Ferro, B J Naume, A Patel, Jens Huober, M J Piccart-Gebhart, J Baselga & E De Azambuja
PATIENTS AND METHODS
Mammography and US were underused in Neo-ALTTO although US had the potential to assess early response whereas mammography to detect residual disease prior to surgery. Our data still emphasise the need for further imaging studies on pts treated with neoadjuvant HER2-targeted therapy.
|citation||Di Cosimo S, Campbell C, Azim H A, Galli G, Bregni G, Curigliano G, Criscitiello C, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, Ng W M J, Colleoni M, Ferro A, Naume B J, Patel A, Huober J, Piccart-Gebhart M J, Baselga J, De Azambuja E. The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. Eur J Cancer 2017; 89:42-48.|
|type||journal paper/review (English)|
|date of publishing||08-12-2017|
|journal title||Eur J Cancer (89)|